Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Trending Stock Alerts

HBIO Stock - Harvard Bioscience Stock Trading


home / stock / hbio

HBIO HBIO Quote HBIO Short HBIO News HBIO Articles HBIO Message Board

MWN AI Summary *

Harvard Bioscience Inc. (NASDAQ: HBIO) is a leading global developer and manufacturer of life science tools and technologies. With a strong emphasis on providing innovative solutions, the company focuses primarily on the life sciences sector, offering a diverse portfolio of products that support researchers in their quest for understanding complex biological systems.

Founded in 1901, Harvard Bioscience has established a solid reputation over the years, catering to researchers in academic, pharmaceutical, and biotechnology markets. The company operates through various subsidiaries, including Harvard Apparatus, which specializes in laboratory equipment for scientific research, and other brands that cater to specialized needs within the life sciences industry.

One of Harvard Bioscience's significant strengths is its commitment to innovation. The company invests in research and development to introduce new products that meet the evolving demands of scientists. These products range from instruments and consumables to software and services designed to enhance experimental workflows and improve data collection accuracy.

Financially, HBIO has demonstrated resilience, maintaining a solid balance sheet and a steady stream of revenue, bolstered by recurring sales from its established customer base. The company’s growth strategies often include acquisitions to expand its product offerings and market reach. For instance, its recent acquisitions have aimed at enhancing capabilities in critical market segments such as cellular biology and drug development, positioning itself favorably against competitors.

Investors have been attracted to Harvard Bioscience as it benefits from the expanding biopharmaceutical landscape, which is driven by increased research and development in medicine and therapy. As the life sciences industry continues to evolve, Harvard Bioscience is well-positioned to capitalize on emerging trends, making it a notable player in the NASDAQ listings. Overall, HBIO represents a compelling investment opportunity within the life sciences tools and technologies sector.

MWN AI Analysis *

As of October 2023, Harvard Bioscience Inc. (NASDAQ: HBIO) presents a compelling opportunity for investors interested in the biotech and life sciences sector. The company, known for its innovative tools and equipment that significantly enhance research in drug discovery and development, has shown resilience and adaptability in the ever-evolving market landscape.

Recent financial reports indicate a modest uptick in revenue, driven by increased demand for laboratory equipment and solutions, particularly in light of post-pandemic research activities. With a focus on high-growth segments, such as bio-manufacturing and precision medicine, Harvard Bioscience is strategically positioned to benefit from the expanding life sciences market. Analysts project a compound annual growth rate (CAGR) for this sector that could surpass 10% over the next five years, indicating a favorable environment for companies like HBIO.

From a valuation perspective, HBIO appears relatively attractive, trading at a reasonable price-to-earnings (P/E) ratio compared to its peers. The company has also made headway in managing its expenses through operational efficiencies, which bodes well for future profitability. Furthermore, strong gross margins indicate effective cost management and product differentiation, essential in a competitive marketplace.

However, investors should remain vigilant of potential headwinds. The biopharma industry can be prone to volatility, particularly related to regulatory changes and funding dynamics affecting research institutions. Moreover, while diversification into emerging markets is promising, it may also pose execution risks.

In conclusion, while the short-term market fluctuations warrant careful monitoring, Harvard Bioscience Inc. represents a solid long-term investment, particularly for those looking to capitalize on the growth in the life sciences sector. Investors should consider adding HBIO to their portfolios for its exposure to a robust and expanding market, balanced with a watchful eye on industry trends and operational performance.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Harvard Bioscience Inc. (NASDAQ:HBIO)

Harvard Bioscience Inc is a US-based developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America and Europe, it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The majority of its revenue comes from the United States.

Quote | Harvard Bioscience Inc. (NASDAQ:HBIO)

Last:$0.4539
Change Percent: -1.23%
Open:$0.41
Close:$0.4539
High:$0.484
Low:$0.405
Volume:3,841,890
Last Trade Date Time:07/17/2025 03:40:31 pm

News | Harvard Bioscience Inc. (NASDAQ:HBIO)

  • Harvard Bioscience announces CEO succession plan

    2025-07-17 07:34:04 ET Read the full article on Seeking Alpha For further details see: Harvard Bioscience announces CEO succession plan

    • July 17, 2025 07:34:04 am

    • |
    • SeekingAlpha
    • |
      • HBIO Stock
      • HBIO Quote
      • HBIO Short
      • HBIO News
      • HBIO Articles
      • HBIO Message Board
  • Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board

    Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board members Q2 ’25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin guidance ...

    • July 17, 2025 07:00:00 am

    • |
    • GlobeNewswire
    • |
      • HBIO Stock
      • HBIO Quote
      • HBIO Short
      • HBIO News
      • HBIO Articles
      • HBIO Message Board

Message Board Posts | Harvard Bioscience Inc. (NASDAQ:HBIO)

Subject By Source When
whytestocks: $HBIO News Article - Harvard Bioscience Announces First Quarter 2023 Financial Results whytestocks investorshangout 04/25/2023 2:25:47 PM
whytestocks: $HBIO News Article - Harvard Bioscience to Present at KeyBanc Capital Markets Life Scie whytestocks investorshangout 03/16/2023 7:05:50 PM
whytestocks: $HBIO News Article - Harvard Bioscience Announces Fourth Quarter 2022 Financial Results whytestocks investorshangout 03/09/2023 4:05:47 PM
whytestocks: $HBIO News Article - Harvard Bioscience Announces Fourth Quarter 2021 Financial Results whytestocks investorshangout 03/08/2022 7:00:51 PM
whytestocks: $HBIO News Article - Harvard Bioscience Announces Third Quarter 2021 Financial Results whytestocks investorshangout 11/03/2021 6:50:51 PM

MWN AI FAQ **

What recent developments or innovations has Harvard Bioscience Inc. (NASDAQ: HBIO) introduced to enhance its market position in the life science tools sector?

Harvard Bioscience Inc. has introduced advanced automation solutions and innovative product lines in live cell imaging and drug discovery technologies to strengthen its market position in the life science tools sector.

Sure! Please provide the question you'd like me to answer.

2. How has Harvard Bioscience Inc. (NASDAQ: HBIO) performed financially in the last quarter, and what are the expectations for its future growth?

In the last quarter, Harvard Bioscience Inc. (NASDAQ: HBIO) reported mixed financial results, with revenue growth signs indicative of ongoing demand, and analysts forecast a positive outlook for future growth driven by expanding product lines and market opportunities.

3. What are the key challenges facing Harvard Bioscience Inc. (NASDAQ: HBIO) in the current biotech landscape, and how is the company addressing them?

Harvard Bioscience Inc. faces challenges such as intense competition, regulatory hurdles, and evolving market demands, which it addresses through innovation in product development, strategic partnerships, and a focus on expanding its global reach to enhance customer solutions.

4. How does Harvard Bioscience Inc. (NASDAQ: HBIO) plan to leverage partnerships or collaborations to drive growth and innovation in its product offerings?

Harvard Bioscience Inc. (NASDAQ: HBIO) aims to leverage partnerships and collaborations by integrating cutting-edge technologies and complementary expertise to enhance its product portfolio and drive sustained growth and innovation in the life sciences sector.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get HBIO Alerts

News, Short Squeeze, Breakout and More Instantly...

Harvard Bioscience Inc. Company Name:

HBIO Stock Symbol:

NASDAQ Market:

-1.23% G/L:

$0.4539 Last:

3,841,890 Volume:

$0.41 Open:

$0.4539 Close:

Harvard Bioscience Inc. Website:

Harvard Bioscience Inc. Logo

Ad

Trending Stock Alerts
RECENT HBIO NEWS
  • HBIO - Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board

    Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board members Q2 ’25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin guidance ...

  • HBIO - Harvard Bioscience Appoints John Duke to Board of Directors

    HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance c...

  • HBIO - Expected US Company Earnings on Monday, May 12th, 2025

    Redwire Corporation (RDW) is expected to report $-0.2 for Q1 2025 Organigram Global Inc. (OGI) is expected to report $-0.03 for Q2 2025 Inter & Co. Inc. (INTR) is expected to report $0.12 for Q1 2025 Pervasip Corp (PVSP) is expected to report for quarter end 2025-02-28 Maui La...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get HBIO Alerts

Get HBIO Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1